Tagrisso Drug Insight And Market Forecast
“Tagrisso - Market Size, Forecast, and Drug Insight – 2034” report by DelveInsight outlays comprehensive insights of the product indicated for the treatment of its approved condition. A detailed picture of the Tagrisso in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020-2034 is provided in this report along with a detailed description of the product. The product details covers mechanism of action, dosage and administration, route of synthesis, and pharmacological studies, including product marketed details, regulatory milestones, and other development activities. Further, it also consists of market assessments inclusive of the market forecast, SWOT analysis, and detailed analyst views. It further highlights the market competitors, late-stage emerging therapies, and patent details in the global space.
Tagrisso Overview
Tagrisso (osimertinib) is a third-generation, oral EGFR tyrosine kinase inhibitor (TKI) developed by AstraZeneca for the treatment of non-small cell lung cancer (NSCLC) with specific EGFR mutations. It is approved for first-line treatment of metastatic EGFR and as adjuvant therapy in early-stage disease. Tagrisso selectively targets EGFR-sensitizing and T790M resistance mutations, offering improved progression-free survival and central nervous system activity compared to earlier-generation EGFR inhibitors.
Why is Tagrisso so expensive?
Tagrisso (osimertinib) is a targeted therapy developed for EGFR-mutated, a specific and genetically defined patient population. The high Tagrisso cost is largely attributed to extensive research and development investments, complex clinical trial programs across multiple treatment lines, and regulatory processes in major markets such as the US, EU, and Japan.
Tagrisso Market Recent Developments
- In January 2026, AstraZeneca Canada is pleased to announce that Tagrisso (osimertinib) and Calquence (acalabrutinib tablets) are now publicly funded in Ontario and are among the first therapies to receive accelerated access through the province's new Funding Accelerated for Specific Treatments (FAST) program. With the introduction of FAST, the Government of Ontario has taken a significant step toward accelerating access to cancer medicines – demonstrating its commitment to putting patients first and embracing innovation so that life-changing treatments can reach those who need them, faster than ever.
Scope of the Tagrisso Market Report
The Tagrisso Market report provides insights into:
- A comprehensive product overview including the product description, mechanism of action, dosage and administration, route of synthesis, pharmacological studies (pharmacodynamics and pharmacokinetics) and adverse reactions.
- Elaborated details on regulatory milestones and other development activities have been provided in this report.
- The Tagrisso Market report also highlights the drug marketed details across the United States, Europe and Japan.
- TheTagrisso Market report also covers the patents information with expiry timeline around Tagrisso.
- TheTagrisso Market report contains historical and forecasted sales for Tagrisso till 2030.
- Comprehensive coverage of the late-stage emerging therapies (Phase III) in the space with a brief snapshot of the details.
- The Tagrisso Market report also features the SWOT analysis with analyst insights and key findings of Tagrisso.
Tagrisso Methodology
The Tagrisso Market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
Tagrisso Analytical Perspective by DelveInsight
- In-depth Tagrisso Market Assessment
This Tagrisso Market report provides a detailed market assessment of Tagrisso in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides historical and forecasted sales data from 2019 to 2032.
- Tagrisso Clinical Assessment
The Tagrisso Market report provides the clinical trials information of Tagrisso covering trial interventions, trial conditions, trial status, start and completion dates.
Tagrisso Market Report highlights
- In the coming years, the market scenario for Tagrisso is set to change due to the extensive research in the treatment of the indicated condition and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
- The Tagrisso companies and academics are working to assess challenges and seek opportunities that could influence Tagrisso dominance. The therapies under development are focused on novel approaches to treat/improve the disease condition.
- Other approved products for the disease are giving market competition to Tagrisso and launch of late-stage emerging therapies in the near future will significantly impact the market.
- A detailed description of regulatory milestones, development activities, and some key findings provide the current market scenario of Tagrisso.
- Our in-depth analysis of the sales data of Tagrisso from 2019 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Tagrisso in the market.
Key Questions Answered In The Tagrisso Market Report
- What is the prescribed dosage and strengths of Tagrisso are available in the market?
- What are the common adverse reactions or side effects of Tagrisso?
- What is the product type, route of administration and mechanism of action of Tagrisso?
- What are the chemical specifications of Tagrisso?
- How are the clinical trials diversified on the basis of the trial status?
- What is the history of Tagrisso, and what is its future?
- What are the marketed details of Tagrisso in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
- How many patents have been granted to Tagrisso and when these patents will get expire?
- What are the pros (benefits) and cons (disadvantages) of Tagrisso?
- In which countries Tagrisso got approval and when it gets launched?
- What are the clinical trials are currently ongoing for Tagrisso?
- How the safety and efficacy results determined the approval of Tagrisso?
- What are the key Tagrisso collaborations, mergers and acquisitions, licensing and other activities related to the Tagrisso development?
- What are the key Tagrisso designations that have been granted to Tagrisso?
- What is the historical and forecasted market scenario of Tagrisso?
- How is the Tagrisso market trend of Tagrisso is different in the Seven Major Markets (the United States, EU5 [Germany, France, Italy, Spain, and the United Kingdom], and Japan)?
- What are the other approved products available and how these are giving competition to Tagrisso?
- Which are the late-stage Tagrisso emerging therapies under development for the treatment of the indicated condition?
